NCT01806610View on ClinicalTrials.gov

Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Interventions
DRUG

BPS804

Single dose BPS804 administration.

DRUG

Placebo

Single dose placebo administration.

Sponsors

Collaborators (2)

Mereo BioPharma
Novartis
All Listed Sponsors
collaborator

Mereo BioPharma

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY